



**Press Release**  
November 15, 2021

## **Invitation to Scandion Oncology A/S webcast and conference call November 18, 2021**

Scandion Oncology A/S will publish its Q3 interim report on Thursday, November 18, 2021 before 09:00 CET.

Scandion Oncology's executive management will host a webcast and conference call the same day at 10:00 CET presenting the results and a company update.

At the end of the presentation there will be a Q&A session.

Access to the event can be obtained as follows:

**LIVE access on Thursday November 18, 2021 at 10:00 CET**

<https://financialhearings.com/event/13910>

**REPLAY access:**

Webcast replay will be available at [www.scandiononcology.com](http://www.scandiononcology.com) in the Investors section and at [www.financialhearings.com](http://www.financialhearings.com)

**For further information regarding Scandion Oncology A/S, please contact:**

Bo Rode Hansen, President & CEO  
Phone: +45 3810 2017  
E-mail: [info@scandiononcology.com](mailto:info@scandiononcology.com)  
Website: [www.scandiononcology.com](http://www.scandiononcology.com)

The information was provided by the contact person above for publication on November 15, 2021.

**About Scandion Oncology A/S**

Scandion Oncology A/S is a clinical Phase II biotechnology company currently developing first-in-class, oral add-on drugs to existing market leading anti-cancer therapies. As add-on to standard anti-cancer therapies, it introduces an effective treatment approach for cancer, which is or has become resistant to cancer-fighting drugs, offering the potential for better response rates, longer survival and improved quality of life. The first-in-class lead candidate, SCO-101, is currently in clinical Phase II. The Company is targeting cancer drug resistance in various treatment modalities including chemotherapy, anti-hormonal therapy and immunotherapy. Scandion Oncology is listed on Nasdaq First North Growth Market Sweden. **Ticker: SCOL.**

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at [ca@vhcorp.se](mailto:ca@vhcorp.se) or +46 (0) 40 200 250.